A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adju

['lizbeth]

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

NCT01358877


This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus Herceptin (trastuzumab) as adjuvant therapy in patients with operable HER2-positive primary breast cancer. After surgery, patients will be randomized to receive either pertuzumab or placebo intravenously (iv) every 3 weeks for one year, in addition to 6-8 cycles of chemotherapy and 1 year of Herceptin (trastuzumab) iv every 3 weeks. Anticipated time on study treatment is 52 weeks. This study will be carried out in collaboration with the Breast International Group (BIG).


http://www.clinicaltrials.gov/ct2/show/study/NCT01358877?term=Her2+breast+cancer&recr=Open&no_unk=Y&phase=2&rank=26&show_locs=Y#locn

['lizbeth]

This is a phase III clinical trial which is accruing worldwide. Many sites say active, not recruiting - I expect that enrollment at that location is full.

If you have finished surgeries but not started chemotherapy please check and see if the trial is recruiting in your area.

This is a great opportunity as Perjeta was just approved for pre-surgery use in some early stage cancer. It has demonstated effectiveness over the standard treatment of a taxane and Herceptin.

[jaykay]

As 'lizbeth says, this is a great trial to try to get into if you are at the beginning of your journey. My onc wanted me to apply last fall but I was rejected because I had a prior breast cancer. Even tho I didn't have chemo or Herceptin - bummer